Skip to the reading
Amino Peptides

BPC-157 has a repair reputation. We look at the research.

The idea is appealing. The evidence in people is still thin.

An older adult and a child considering a board game together on a blue rug
Ordinary plans are part of what makes a repair question matter.

Which amino acids are in BPC-157?

BPC-157 is a lab-made chain of fifteen amino acids, the building blocks used in proteins. The FDA records its makeup: glycine, glutamic acid, proline, lysine, alanine, aspartic acid, leucine and valine. Some appear more than once.

Its design follows part of a protein that researchers reported finding in stomach juice. That doesn’t make BPC-157 a natural medicine your body already produces.

You don’t need to learn the whole chain to follow the repair question. What matters is whether it helps a particular injury in people, and what risks come with it. The name alone can’t answer either part.

Why researchers are interested

A blood-vessel study found more vessel growth in lab experiments and better blood-flow recovery in rats. New blood vessels are part of the proposed repair story. The work offers a reason to investigate further.

It didn’t show that someone’s tendon healed faster. Some experiments used human cells, but cells in a dish aren’t people recovering from an injury. We keep that distinction beside the finding, where it’s harder to miss.

What we know from people

A 2025 safety pilot gave BPC-157 by intravenous infusion to two adults and reported no adverse events. It wasn’t a test of injury recovery. Two people also can’t tell us how often uncommon harms might happen.

A review that year found only three published human pilot studies and called for larger, stronger trials. That’s the evidence the review covered, rather than a count of every study ever attempted. We don’t yet have a dependable human repair answer.

Safety is still an open question

The FDA’s page current as of April 22, 2026 lists BPC-157 as nominated but withdrawn. It still raises concerns about immune reactions, impurities and limited safety information. A withdrawn request isn’t FDA clearance.

Long-term human safety remains uncertain. That gap belongs in the conversation about repair, even when the early findings sound encouraging. Our access page explains why a prescription and FDA approval are separate things.

We can stay interested without calling it settled.

For an injury question, we look for recovery in people with that injury. The early work gives researchers something to pursue. It leaves readers with real gaps to weigh.